NPM1 and acute myeloid leukemia: About 30% of patients with normal karyotype AML expose a mutation in NPM1 (Nucleophosmin 1) gene, which is assumed to be relatively stable during disease course hereby fulfilling a major requirement for a suitable MRD marker [11,38,39].